MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma
Buffalo, NY. October 12, 2023– MimiVax, Inc., a biotechnology company focused on the development of glioblastoma vaccine therapy, announced today that the United States Food and Drug Administration (FDA) has granted Fast Track... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 12, 2023 Category: Pharmaceuticals Source Type: clinical trials
A Single Center, Single Arm Phase I Clinical Study of GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors
Conditions: Adult Interventions: Biological: GT101 Sponsors: Grit Biotechnology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 11, 2023 Category: Research Source Type: clinical trials
GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors
Conditions: Adult Interventions: Biological: GT101 Sponsors: Grit Biotechnology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 11, 2023 Category: Research Source Type: clinical trials
An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
Conditions: Advanced Solid Tumors Interventions: Drug: SG1827 Sponsors: Hangzhou Sumgen Biotech Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 10, 2023 Category: Research Source Type: clinical trials
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
Conditions: Generalized Epidermolysis Bullosa Simplex Interventions: Drug: AC-203; Drug: Vehicle Sponsors: TWi Biotechnology, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 9, 2023 Category: Research Source Type: clinical trials
A Phase I Study of RC1416 Injection
Conditions: Healthy Volunteers Interventions: Drug: RC1416(SAD); Drug: Placebo(SAD) Sponsors: Nanjing RegeneCore Biotech Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials
the Safety and Efficacy of SENL103 Autologous T Cell Injection
Conditions: Multiple Myeloma Interventions: Biological: SENL103 Sponsors: Hebei Senlang Biotechnology Inc., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials
Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body
Conditions: Bioequivalence; Schizophrenia Interventions: Drug: Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd. Sponsors: The Affiliated Hospital of Qingdao University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024
PRINCETON, N.J.--(BUSINESS WIRE)--Oct. 3, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it has reached... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 3, 2023 Category: Pharmaceuticals Source Type: clinical trials
Post-Procedural Biotech Cellulose Mask
Conditions: Temperature Change, Body Interventions: Other: Velez Intense Hydration Mask ® (biotech cellulose face mask) Sponsors: Siperstein Dermatology Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
Avenge Bio Receives FDA Fast Track Designation for AVB-001, a Novel Cell Therapy Leveraging the LOCOcyte ™ Immunotherapy Platform
NATICK& QUINCY, Mass., Oct. 2, 2023 /PRNewswire/ -- Avenge Bio, Inc. ( " Avenge " or the " Company " ), a biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision administration of potent immune effector molecules... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 2, 2023 Category: Pharmaceuticals Source Type: clinical trials
Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial
Conditions: Hand, Foot and Mouth Disease; Herpangina Interventions: Biological: low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated; Biological: medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated; Biological: high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated; Biological: Enterovirus type EV71 vaccine (Vero cell), Inactivated Sponsors: Sinovac Biotech Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials
Immunogenicity of After Primary Immunization and Booster Immunization of sIPV
Condition: Polio Intervention: Other: no intervention Sponsors: Sinovac Biotech Co., Ltd; Jiangxi Center for Disease Control and Prevention Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old
Condition: Hepatitis A Intervention: Biological: Healive (hepatitis A vacine(human diploid cell), inactivated) Sponsors: Sinovac Biotech Co., Ltd; Liaoning Center for Disease Control and Prevention Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
RY_SW01 Cell Injection Therapy in Systemic Sclerosis
Condition: Systemic Sclerosis Interventions: Drug: RY_SW01 cell injection; Drug: Basic treatment Sponsors: Jiangsu Renocell Biotech Company; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
